P.346 Concomitant Sjögren’s syndrome as a marker for severe visceral disease in systemic sclerosis
Rattachement africain : ca. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Introduction The prevalence of sicca and/or objective signs of Sjogren’s syndrome (SjS) in systemic sclerosis (SSc) patients varies from 1/3 and higher.1 2 The differences between patients with SSc+SjS vs SSc and no SjS with respect to manifestations, functional status and quality of life remain unclear. Our study aimed to characterize the clinical phenotype of SSc patients with concomitant SjS. Material and Methods Data were obtained from the Canadian Scleroderma Research Group registry; an observational multicentre database of 1293 SSc patients (87% female; mean±SD age 55.2±12.1 yrs; disease duration 10.4±9.4 yrs) who were categorized according to the presence or absence of SjS. SjS was defined as giving 3 or more positive answers to 6 sicca symptom questions OR 2 or more positive answers AND 1 or more signs of xerostomia/xerophthalmia. Skin was assessed using modified Rodnan Skin Score (mRSS), overall disease severity - by the summed Medgser disease severity score (DSS), patient and physician global assessments, HAQ-DI, Scleroderma HAQ (SHAQ) and SF-36v2. Sub-group analyses were done in limited and diffuse cutaneous SSc. Bivariate, ANOVA, non-parametric, and chi-squared tests and multivariate regression analysis were used. Results We identified 386 SSc+SjS patients (30%) who were more likely to be female (93% vs 84%, p<0.001) with a longer disease duration (12.4±9.9 vs 9.5±9.0 years, p<0.001) compared to no SjS. SjS-SSc patients showed a more severe disease (DSS total 9.1±4.1 vs 8.3±3.8, p=0.005; patient global assessment of health 4.2±2.4 vs 3.0±2.4, p<0.001; physician-reported disease severity 2.8±2.0 vs 2.7±2.3, p=0.025), specifically lung and gastrointestinal involvement (table 1). They also reported worse functional status (p<0.001 for all HAQ-DI, SHAQ ulcers/Raynaud’s phenomenon/breathing), but there was no difference in SF-36 summary scores and separate domains between patients with and without SjS. A higher frequency of ACA-positivity (42% vs 31%, p<0.001) and less severe skin involvement (mRSS 8.6±9.2 vs 10.0±9.6, p<0.008) were found in SSc-SjS patients. Sub-group analysis showed more severe disease and worse HAQ/SHAQ in SjS-SSc patients, regardless of SSc subtype (table 1). SjS remained a significant independent predictor for disease severity after controlling for confounding by age, sex, disease duration, mRSS, disease activity and SSc-specific autoantibodies in multivariate regression analysis (p<0.001). Conclusions Despite a prevalent ACA+ subtype with less skin involvement, SSc-SjS patients revealed a more severe SSc with predominant lung disease affecting significantly their functional status. References Couderc M, et al. Ann Rheum Dis. 2020;79:e137. Kobak S, et al. Int J Rheum Dis. 2013;16:88–92.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- P.346 Concomitant Sjögren’s syndrome as a marker for severe visceral disease in systemic sclerosis
- Date Crossref
- 01/06/2026
- Éditeur
- BMJ Publishing Group Ltd
- Type
- proceedings-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Western University pays non établi dans la noticeUniversité ou école supérieure
-
University of Calgary pays non établi dans la noticeUniversité ou école supérieure
-
Jewish General Hospital pays non établi dans la noticeÉtablissement de santé
-
McGill University pays non établi dans la noticeUniversité ou école supérieure
-
Université de Montréal pays non établi dans la noticeUniversité ou école supérieure
-
University of Alberta pays non établi dans la noticeUniversité ou école supérieure
-
University of Alberta Hospital pays non établi dans la noticeÉtablissement de santé
-
Southlake Regional Health Center pays non établi dans la noticeÉtablissement de santé
-
University of Western Ontario pays non établi dans la noticeUniversité ou école supérieure
-
University of Montreal pays non établi dans la noticeUniversité ou école supérieure
-
Southlake Regional Health Centre pays non établi dans la noticeÉtablissement de santé
Western University, University of Calgary et Jewish General Hospital, avec 8 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.